Trial Profile
A Retrospective Study Investigating Clinical Outcome of Patients with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) treated with Pembrolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.